Immunosuppressants - Serbia

Serbia

Highlights

in Serbia, a country in southeastern Europe, is expected to contribute to the revenue growth in the Immunosuppressants market.
According to projections, the market's revenue is set to reach US$14.66m in 2024.
This growth is anticipated to continue with an annual growth rate of 15.53% from 2024 to 2029.
By the end of this period, the market volume is estimated to reach US$30.18m.
In comparison to other countries, United States is expected to generate the highest revenue in the Immunosuppressants market.
In 2024, the revenue United States is projected to reach a staggering US$35.47bn.
This highlights the significant market presence and potential of the United States in this market.
The demand for immunosuppressants in Serbia has been steadily increasing due to the rising prevalence of autoimmune diseases.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The demand for immunosuppressants in Serbia has been on the rise in recent years, driven by various factors such as the increasing prevalence of autoimmune diseases and organ transplantation procedures.

Customer preferences: Patients in Serbia prefer immunosuppressants that are effective in managing their conditions while minimizing side effects. They are also increasingly seeking out more affordable options due to the high cost of some immunosuppressant drugs.

Trends in the market: One of the major trends in the Serbian immunosuppressants market is the increasing use of biosimilars. Biosimilars are cheaper alternatives to biologic drugs that have the same efficacy and safety profile. The Serbian government has been actively promoting the use of biosimilars in an effort to reduce healthcare costs. Another trend is the growing demand for small molecule immunosuppressants, which are easier to administer and have fewer side effects compared to biologic drugs.

Local special circumstances: Serbia has a relatively small market for immunosuppressants compared to other European countries. This is partly due to the country's lower healthcare spending and the limited availability of certain drugs. However, the market is expected to grow in the coming years due to the increasing prevalence of autoimmune diseases and the government's efforts to improve healthcare access and affordability.

Underlying macroeconomic factors: Serbia's economy has been growing steadily in recent years, with a focus on attracting foreign investment and expanding its export market. This has led to increased government spending on healthcare and infrastructure, which is expected to benefit the immunosuppressants market. However, the country still faces challenges such as high unemployment and a large informal economy, which may limit the growth of the healthcare sector.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.